Cytokinetics (CYTK) Amortization of Deferred Charges (2015 - 2016)
Cytokinetics (CYTK) posted quarterly Amortization of Deferred Charges of $139000.0 for Q4 2016, up 4533.33% year-over-year from $3000.0 in Q1 2016, and up 0.72% quarter-over-quarter from $138000.0 in Q3 2016.
Cytokinetics (CYTK) Amortization of Deferred Charges (2015 - 2016) Analysis & Trends
Cytokinetics (CYTK) has reported Amortization of Deferred Charges for 2 consecutive years, with $139000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Amortization of Deferred Charges rose 4533.33% year-over-year to $139000.0; the TTM figure through Dec 2016 stood at $534000.0 (up 17700.0% YoY), while the FY2016 annual figure was $534000.0, up 17700.0% from the prior year.
- Amortization of Deferred Charges advanced to $139000.0 in Q4 2016 per CYTK's latest filing, from $138000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $139000.0 in Q4 2016 and bottomed at $3000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 139,000.00 |
| Dec 31, 2016 | 139,000.00 |
| Sep 30, 2016 | 138,000.00 |
| Sep 30, 2016 | 138,000.00 |
| Jun 30, 2016 | 138,000.00 |
| Jun 30, 2016 | 138,000.00 |
| Mar 31, 2016 | 119,000.00 |
| Mar 31, 2016 | 119,000.00 |
| Dec 31, 2015 | 3,000.00 |
| Dec 31, 2015 | 3,000.00 |